Carboplatin may interact with aluminium to form block precipitate. Needles, syringes, catheters or i.v. administration sets that contains aluminium parts which may come in contract with Carboplatin should not be used for preparation or administration of the drug. Concurrent therapy with nephrotoxic drugs may increase or exacerbate toxicity due to Carboplatin included changes in renal clearance. Combination therapy with other myelosuppressive drugs may cause consideration to altering the dose or timing of Carboplatin therapy in order to minimize additive myelosuppressive effects.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
